Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Cancer immunotherapy stories

Nov 16, 2026

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.

Nov 16, 2026·3 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Nov 6, 2026

Moderna posts first quarterly profit in two years, raises revenue forecast

Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.

Nov 6, 2026·5 sources
00
Nov 5, 2026

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Nov 4, 2026

Sino Biopharmaceutical signs cancer deal worth up to $7 billion with Boehringer Ingelheim

Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.

Nov 4, 2026·3 sources
00
Oct 30, 2026

Hiroshima University finds hyperactive YAP/TAZ proteins help cancer cells evade immune system

Researchers at Hiroshima University and international collaborators discovered that hyperactive YAP and TAZ proteins, which promote cancer, are associated with genomic instability that enables tumor cells to evade immune system detection and destruction.

Oct 30, 2026·2 sources
00

Mayo Clinic study finds checkpoint immunotherapy reshapes immune environment in melanoma-affected lymph nodes

A new Mayo Clinic study reveals that checkpoint immunotherapy may reorganize the immune environment within lymph nodes after melanoma has spread to them. The research demonstrates how the treatment restructures immune cell interactions in affected lymph nodes.

Oct 30, 2026·2 sources
00

Fox Chase Cancer Center identifies ANO6 protein as target to slow pancreatic cancer growth

Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Roswell Park researchers identify timing window for immunotherapy in prostate cancer treatment

Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.

Oct 29, 2026·1 source
00

Study links type 1 diabetes immune changes to potential cancer protection

New research published in The Journal of Immunology reveals how high blood sugar and type 1 diabetes may protect against certain cancers including melanoma, breast and colon cancer. The findings could inform development of new cancer immunotherapy treatments by explaining the previously mysterious association between T1D and decreased cancer risk.

Oct 29, 2026·1 source
00
Oct 28, 2026

Genmab's petosemtamab cuts death risk by half in head and neck cancer trial

Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.

Oct 28, 2026·3 sources
00
Oct 27, 2026

BYU researchers develop MOTO-CAR macrophage therapy to target solid tumors in preclinical study

Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.

Oct 27, 2026·2 sources
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00

Nearly 30% of advanced melanoma patients achieve complete tumor disappearance with lifileucel TIL therapy plus pembrolizumab

Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.

Oct 24, 2026·1 source
00
Oct 23, 2026

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00
Oct 6, 2026

Caribou Biosciences halts CAR-T programs and seeks strategic alternatives after failing to secure funding

Caribou Biosciences, a CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, announced it will discontinue its two allogeneic CAR-T cell therapy programs and lay off staff after failing to secure funding for a pivotal lymphoma trial. The company's stock plunged 40% following the announcement as it explores strategic alternatives.

Oct 6, 2026·7 sources
00
Sep 19, 2026

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Sep 8, 2026

Bristol Myers CAR-T therapy shows high response rate in treatment-resistant blood cancer

Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.

Sep 8, 2026·3 sources
00
Sep 1, 2026

Roche licenses tri-specific antibody from Simcere for blood cancer

Roche signed a global licensing agreement with China's Simcere for an experimental tri-specific antibody targeting blood cancers, expanding its oncology pipeline.

Sep 1, 2026·2 sources
00
Aug 28, 2026

BioNTech halts colorectal cancer vaccine trial after safety review finds treatment unlikely to extend survival

BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.

Aug 28, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 15, 2026

Innovent Biologics doses first patient in phase 3 trial of IBI363 for advanced colorectal cancer

Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.

Aug 15, 2026·1 source
00
Aug 12, 2026

Scientists develop genetic tool to make soft tumors vulnerable to CAR-T cell therapy

Researchers at USC have engineered a genetic tool that addresses a major obstacle in cancer immunotherapy by targeting the physical softness of solid tumors, potentially enabling CAR-T cell therapy to work against cancers it previously couldn't treat effectively.

Aug 12, 2026·2 sources
00
Aug 2, 2026

CRISPR makes prostate cancer vulnerable to immunotherapy in mice

Scientists used CRISPR gene editing to make prostate cancer cells easier for the immune system to detect and destroy, dramatically improving immunotherapy effectiveness in mice.

Aug 2, 2026·1 source
00
Jul 31, 2026

FDA Advisory Committee Votes 10-3 in Favor of Replimune's RP1 Efficacy Data from Ignyte Study

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.

Jul 31, 2026·1 source
00
Jul 30, 2026

Johnson & Johnson secures option to acquire CAR-T biotech Sail Biomedicines for $2.6 billion

J&J has obtained an option to purchase Sail Biomedicines, a Flagship Pioneering-backed startup developing 'in vivo' CAR-T therapies, in a deal valued at nearly $2.6 billion.

Jul 30, 2026·1 source
00

Merseyside Woman Becomes First Patient Worldwide to Receive New Lung Cancer Vaccine in Clinical Trial

A lung cancer patient from Merseyside has become the first person in the world to receive a new experimental vaccine as part of an early-stage clinical trial involving 10 patients.

Jul 30, 2026
00
Jul 25, 2026

Engineered probiotic bacteria show promise in boosting immune response against pancreatic cancer

Researchers have developed engineered probiotic bacteria designed to overcome the 'cold' tumor microenvironment in pancreatic cancer, potentially enhancing the effectiveness of immunotherapy treatments for this difficult-to-treat disease.

Jul 25, 2026·1 source
00
Jul 24, 2026

Study Identifies Germline Variants Linked to Yescarta CAR-T Toxicity and Expansion

New research analyzing patients from Kite Pharma's Yescarta clinical trials has identified inherited genetic signatures that can predict which patients are at higher risk for toxic side effects from CAR-T cell therapy, potentially enabling better patient selection and monitoring for this cancer immunotherapy.

Jul 24, 2026·4 sources
00
Jul 4, 2026

Phase Ib Trial Shows Safety of Personalized Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma

Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.

Jul 4, 2026·2 sources
00
Jun 22, 2026

China Approves World's First CAR-T Therapy for Solid Tumors to Treat Advanced Gastric Cancer

China's National Medical Products Administration has approved satricabtagene autoleucel (Satri-cel, CT041, Kaileimei®), marking the first CAR-T cell therapy approved globally for treating solid tumors, specifically for CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.

Jun 22, 2026·4 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
Apr 22, 2026

Immunotherapy Shows Clinical Benefit in Advanced Colorectal Cancer as First-Line Treatment

Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.

Apr 22, 2026·2 sources
00
Apr 19, 2026

Researchers Develop Method to Supercharge Cancer-Killing Immune Cells

Scientists found a way to make cancer-killing immune cells more powerful and precise by adding specific signaling components that boost the cells' readiness to attack tumors, offering a new approach to immunotherapy.

Apr 19, 2026·1 source
00

mRNA Cancer Vaccines Show Effectiveness Even Without Key Immune Cells in New Research

Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.

Apr 19, 2026·1 source
00

Top claims

  • ▪Approximately 75% of newly diagnosed bladder cancers are non-muscle-invasive, a form of the disease that can recur and potentially grow into the bladder muscle
  • ▪Following the announcement of positive Phase 3 trial results on November 16, 2026, CG Oncology shares rose more than 30% to $98 in premarket trading
  • ▪Standard monitoring for intermediate-risk non-muscle-invasive bladder cancer requires patient evaluations every three months, with repeat surgical procedures performed whenever the cancer recurs

People involved

Robert F. Kennedy Jr.

Subtopics

Cancer & Oncology26Drug Policy, Pricing & Approval17Clinical trials16Drug Approval and Clinical Trials16Cancer treatment12Cancer treatment breakthroughs11Oncology10Cancer research7Immunotherapy7MRNA vaccine technology7Biomedical research6Pharmaceutical Industry6Vaccines and Immunization Policy6Cancer and Cancer Treatment5Cancer Types5CAR T-cell therapy5Drug development5Personalized medicine5Vaccine development5Cancer Treatment & Therapies4Immunology4Pharma4Vaccine development and innovation4Clinical evaluation3

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories